Multiplexed Diagnostics: Is Your Business Ready to Adopt These Next-Generation Testing Techniques?

Highlights:

• What are the latest developments in multiplexed diagnostics?
• How can multiplexed diagnostics be valuable for your business?
• Predictions of leading companies in this domain

In the last few years, the growing severity of infectious diseases and the weak resistance of individuals towards such chronic diseases have increased the need for multiplexed diagnostics than ever before. Multiplexed diagnostics are advanced methods of testing that can detect and identify multiple biomarkers in a single test. This approach allows scientists to better understand the biological system of viruses or bacteria, thus helping them find appropriate solutions to treat diseases.

What latest techniques in multiplexed diagnostics can help your business stay ahead of the curve?

Recently, clinically available multiplexed diagnostic approaches have started emphasizing the detection of protein or peptide biomarkers along with nucleic acid testing. LFA (lateral flow assay) has come out as an effective technique that can routinely be used to detect protein or peptide biomarkers in human samples including blood, serum, saliva, and urine. This diagnostic approach has lower sensitivity compared to molecular diagnostic tests and offers rapid test options at cheaper prices.

Another emerging technique in this field is ELISA (enzyme-linked immunosorbent assays) technique. This is a highly sensitive technique for identifying protein and peptide biomarkers. ELISA includes spatial multiplexing approaches such as wells and microarrays to develop a multiplex test. For nucleic acid testing, PCR (polymerase chain reaction) has evolved as the standard amplification method that can help perform multiplexed diagnostic assays by optimizing stringent reaction conditions and other parameters.

How can multiplexed diagnostics bring immense growth opportunities for your business?

Multiplexing can help eliminate the need for different samples to be taken from individuals, saving their time and money while offering rapid and effective testing options. For example, according to UT Southwestern Medical Center, multiplexing tests have helped diagnose cancer earlier among individuals living in underserved communities, with fewer visits.

Additionally, with these advanced testing options, clinicians can identify the root cause of many diseases, especially infectious diseases that possess overlapping symptoms. For instance, the presence of the Covid-19 virus can show similar symptoms of different strains of influenza or respiratory syncytial viruses. Based on the types of products used in multiplex testing, the kits & reagents segment is expected to hold the highest share by garnering a revenue of $18.014,41 million in the 2022-2032 period.

However, multiplexing also reduces the overuse of antibiotics for virus-related respiratory illnesses such as common cold, sinus infections, and bronchitis. It reduces the chances of serious health complications, diagnosing specific illnesses and determining what medications are appropriate for them.

Predictions of top companies

PathogenDx, a leading provider of microarray technology and solutions, predicts that its patented multiplexed molecular testing technology, namely - D3 Array™ can overcome the sensitivity and multiplexing limitations of qPCR.

According to Anurup Ganguli, co-founder and chief executive officer of VedaBio, its newly launched CRISPR Cascade, an advanced platform offering instant molecular detection, can emerge as a futuristic molecular detection method, empowering research, diagnostics, and therapeutics.

NIH (National Institutes of Health) anticipates that the development of a multiplex respiratory diagnostic test by Sapphiros, a leading AI-based computational biology company, can become a game-changing multiplexed diagnostics solution. This solution can rapidly detect influenza A, influenza B, Covid-19, and respiratory syncytial virus in a single test.

To conclude, the increasing prevalence of chronic diseases such as cancers and bacterial infections among people globally can boost the demand for the multiplexed diagnostics industry in the coming years. Moreover, the domain will also flourish with the increasing technological advancements for developing cost-effective and accurate diagnostic tools to treat patients with enhanced precision.

To gain detailed insights into the multiplexed diagnostics industry, feel free to contact our experts today!

Related Post